In January 2014, Novartis announced plans to cut 500 jobs from its pharmaceuticals division.  In February 2014, Novartis announced that it has acquired CoStim Pharmaceuticals.  In May 2014, Novartis bought the rights to market Ophthotech 's Fovista (an anti- PDGF aptamer , also being investigated for use in combination with anti- VEGF treatments) outside the United States for up to $1 billion.  Novartis will acquire exclusive rights to market the eye drug outside of America whilst retaining US marketing rights. The company agreed to pay Ophthotech $200 million upfront, and $130 million in milestone payments relating to Phase III trials.  Ophthotech is also eligible to receive up to $300 million dependent upon future marketing approval milestones outside of America and up to $400 million relating to sales milestones.  In September 2014, Ophthotech received its first $50 million phase III trial milestone payment from Novartis.  In April 2014, Novartis announced that it would acquire GlaxoSmithKline 's cancer drug business for $16 billion as well as selling its vaccines business to GlaxoSmithKline for $ billion.  In August 2014 Genetic Engineering & Biotechnology News reported that Novartis had acquired a 15% stake in Gamida Cell for $35 million, with the option to purchase the whole company for approximately $165 million.  In October 2014, Novartis announced its intention to sell its influenza vaccine business (inclusive of its development pipeline), subject to regulatory approval, to CSL for $275 million. 
The Internet of Things must address the reliable and timely delivery of information, regardless of cyber-threats, using secure automatic processes over distributed and heterogeneous computing systems. IJITCA provides an embedded security, information assurance and cyber-security research perspective, illustrating how cyber-assurance must integrate with IoT devices and networks to understand how these individual components interact in ways to resist and avoid intentional attempts to compromise normal operations. IJITCA addresses the protection of IoT networks from mobile devices to complex processing systems.